Efficient assessment of drug safety and toxicity can be a complex and time consuming matter. We develop and deliver integrated cardiovascular services to enhance the assessment of cardiac safety and toxicity of drug candidates.
We combine our cardiovascular knowledge with expertise on hiPSC-derived cardiomyocyte manufacturing to offer you predictive and translational in vitro disease models, and assays for efficacy screening at any throughput.
Stefan is the Chief Executive Officer of Ncardia. He obtained a MSc and PhD (both cum laude) in stem cell biology under supervision of Prof. Dr Mummery, and brings over a decade of experience in stem cell research and product development. As key inventor of the underlying Pluriomics technologies he has been instrumental in the establishment and growth of the company.
Marijn is VP Technology at Ncardia. She obtained her PhD at the Netherlands Cancer Institute. Marijn has published in various peer-reviewed scientific journals, and has been instrumental in securing grants and commercial research collaborations on various topics.
Roman is our Director of BD & Sales in Europe. He has a background in biology and gained commercial experience in the stem cell industry. He is the direct contact person for our german speaking customers.
Mieke is Product Marketing Manager at Ncardia. She holds a PhD obtained at the Laboratory for Molecular Stem Cell Biology at the Heinrich-Heine University of Dusseldorf, and has extended commercial and marketing experience from several leading biotech companies.
Felix is VP Sales & Business Development. He obtained an MBA at the University of Cambridge and has extended commercial experience in the stem cell market and drug discovery.
Alexandre has over 15 years' experience in the biotech industry where he occupied various functions. At Ncardia he is responsible for sales and business development of our products and services in Southern Europe.
Tristan is our BD & Sales Manager for Northern Europe. He has a background in engineering and stem cell scale-up production. For the past years he has been involved in business development of novel stem cell derived technologies.
Tessa has extended expertise in hiPSC derived cardiac cells, and cell-based assays for drug safety and efficacy screenings. She has completed her masters in Bio-Pharmaceutical Sciences at the Leiden University and leverages her expertise supporting partners and customers in performing their assays.
Charlotte is our Head of Logistics. Her background in industrial management and economic psychology has helped extend superior commercial team customer services in logistics, order processing and post-sales customer services throughout the industry.
Ralf has extended expertise in hiPSC derived cardiac cells, and cell-based assays for drug safety and efficacy screenings. He obtained his PhD at the University of Bonn focussing on aortic vascular smooth muscle cells. With over 16 years of experience with pluripotent stem cell-derived cardiomyocytes, he uses this knowledge for support to our customers and partners.
Thomas our Marketing Manager. He obtained a PhD at the University of Cologne. At Ncardia he is responsible for organizing all marketing activities.
Silvina obtained her PhD in neurobiology. She gained experience in applied solutions for the pharmaceutical industry when working at Galapagos and Charles River. As a Project Manager at Ncardia, she will use her experience in our Safety and Efficacy Services that we offer to our customers.
Petra is responsible for the customer support regarding the use of human iPSC-derived cardiomyocytes for safety pharmacology studies. She obtained her PhD with research focusing on non-alcoholic fatty liver disease and atherosclerosis.
Dietmar is the neuroscience specialist at Ncardia. In combination with his electrophysiology expertise, he has the knowledge to support our customers using neural cells.
Learn more about our latest news, the events where you can meet us, and be inspired by reading about our innovations.